UroToday5d
Clarity and Nucleus RadioPharma Sign Master Services Agreement and Cu-67 SAR-bisPSMA Clinical Supply Agreement
The Master Services Agreement (MSA) and Clinical Supply Agreement with Nucleus RadioPharma complement the existing agreement with NorthStar Medical Radioisotopes, LLC (NorthStar) for 67Cu-SAR-bisPSMA ...
UroToday10d
Leaders in Radiopharmaceuticals: Disruptive Innovations and Personal Perspectives
Radiopharmaceuticals and Combination Approaches in Advancing the Prostate Cancer Treatment Landscape - Philip Kantoff ...
UroToday3d
Efficacy and Safety of Artificial Urinary Sphincters in Female Patients With Stress Urinary Incontinence: A Systematic Review and Meta-Analysis
Stress urinary incontinence (SUI) significantly affects the quality of life in women, causing social, psychological, and physical distress. While artificial urinary sphincter (AUS) implantation is a ...
UroToday3d
Update on PSMA-based Prostate Cancer Imaging.
The increased use of prostate-specific membrane antigen (PSMA) based PET imaging for prostate cancer (Pca) detection has revolutionized the clinical management of Pca, with higher diagnostic ...
UroToday3d
Oncological outcomes of organ-sparing cystectomy versus standard radical cystectomy in male patients diagnosed with bladder cancer.
To compare the oncological outcomes between standard radical cystectomy (SRC) and organ-sparing cystectomy (OSC) in male patients diagnosed with bladder cancer. Patients with stage Ta-T3 bladder ...
UroToday3d
A National Study of the Rate of Benign Pathology After Partial Nephrectomy for T1 Renal Cell Carcinoma: Should We Be Satisfied?
Objectives: To determine the rate of benign pathology in cT1 tumors following partial nephrectomy in the Netherlands, thereby evaluating the rate of overtreatment. Methods: Data were collected from a ...
UroToday3d
Use of Placebo in Urologic Oncology Randomized Controlled Trials.
Use of placebo in oncology randomized controlled trials (RCT) is ethically controversial. Placebo may introduce bias, as toxicity profiles of treatment arms can inadvertently unblind subjects and ...
UroToday3d
Urethral Bulking.
This Clinical Practice Statement aims to provide clinicians with evidence-based guidance for the use of urethral bulking agents (UBAs) in the treatment of stress urinary incontinence (SUI). We ...
UroToday3d
Evaluating the Role of Ultrasound in Prostate Cancer trial - phase 1: Early experience of micro-ultrasound in the United Kingdom.
The purpose of this study was to evaluate if the use of micro-ultrasound can detect clinically significant prostate pathology when compared to histology obtained during a transperineal prostate biopsy ...
UroToday3d
Human papillomavirus (HPV) and Epstein-Barr virus (EBV) in Penile Cancer in Thailand.
Human papillomavirus (HPV) and Epstein-Barr virus (EBV) are important etiological factors for several cancers. This study aimed to determine the prevalence of HPV and EBV infection in penile cancer.
UroToday3d
Tumor regression after neoadjuvant hormonal therapy in high risk prostate cancer: pathological outcomes from a randomized phase II trial.
High-risk localized prostate cancer (HRLPC) commonly progresses to metastatic disease after local treatment. Neoadjuvant androgen deprivation therapy (nADT) before radical prostatectomy (RP) has ...
UroToday3d
Repeatability of quantitative MR fingerprinting for T1 and T2 measurements of metastatic bone in prostate cancer patients.
MR fingerprinting (MRF) has the potential to quantify treatment response. This study evaluated the repeatability of MRF-derived T1 and T2 relaxation times in bone metastasis, bone, and muscle in ...